Rubina Rizvi1, Mehrnaz Hojjati. Show Affiliations » 1. Department of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN, USA.
Abstract
Entities: Disease Species
Mesh： See more » Antirheumatic Agents/therapeutic useAntiviral Agents/adverse effectsAntiviral Agents/therapeutic useDrug Therapy, CombinationHepatitis C, Chronic/drug therapyHumansHydroxychloroquine/therapeutic useImmunosuppressive Agents/therapeutic useInterferon alpha-2Interferon-alpha/adverse effectsInterferon-alpha/therapeutic useLupus Erythematosus, Systemic/chemically inducedLupus Erythematosus, Systemic/diagnosisLupus Erythematosus, Systemic/drug therapyMaleMiddle AgedPolyethylene Glycols/adverse effectsPolyethylene Glycols/therapeutic useRecombinant ProteinsTacrolimus/analogs & derivativesTacrolimus/therapeutic useTreatment Outcome
Substances： See more » Antirheumatic AgentsAntiviral AgentsImmunosuppressive AgentsInterferon alpha-2Interferon-alphaRecombinant ProteinsPolyethylene GlycolsHydroxychloroquinepimecrolimuspeginterferon alfa-2aTacrolimus
Year: 2011 PMID： 21441813 DOI： 10.1097/RHU.0b013e31821557e7
Source DB: PubMed Journal: J Clin Rheumatol ISSN： 1076-1608 Impact factor: 3.517